Free Trial
NASDAQ:NKTR

Nektar Therapeutics (NKTR) Stock Price, News & Analysis

Nektar Therapeutics logo
$0.84 -0.02 (-2.74%)
As of 01:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Nektar Therapeutics Stock (NASDAQ:NKTR)

Key Stats

Today's Range
$0.81
$0.89
50-Day Range
$0.66
$1.06
52-Week Range
$0.65
$1.93
Volume
740,665 shs
Average Volume
1.87 million shs
Market Capitalization
$155.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.92
Consensus Rating
Buy

Company Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Remove Ads

Nektar Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

NKTR MarketRank™: 

Nektar Therapeutics scored higher than 89% of companies evaluated by MarketBeat, and ranked 116th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nektar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Nektar Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Nektar Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Nektar Therapeutics are expected to decrease in the coming year, from ($0.72) to ($0.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nektar Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nektar Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nektar Therapeutics has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Nektar Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.72% of the float of Nektar Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Nektar Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nektar Therapeutics has recently decreased by 11.50%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Nektar Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Nektar Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.72% of the float of Nektar Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Nektar Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nektar Therapeutics has recently decreased by 11.50%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Nektar Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Nektar Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    9 people have searched for NKTR on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,415.00 in company stock.

  • Percentage Held by Insiders

    Only 3.71% of the stock of Nektar Therapeutics is held by insiders.

  • Percentage Held by Institutions

    75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nektar Therapeutics' insider trading history.
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Stock News Headlines

Nektar management to meet with Piper Sandler
Has Trump finally met his match?
Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?
HC Wainwright Has Optimistic Outlook of NKTR Q1 Earnings
See More Headlines

NKTR Stock Analysis - Frequently Asked Questions

Nektar Therapeutics' stock was trading at $0.93 at the start of the year. Since then, NKTR shares have decreased by 10.6% and is now trading at $0.8310.
View the best growth stocks for 2025 here
.

Nektar Therapeutics (NASDAQ:NKTR) posted its earnings results on Wednesday, March, 12th. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.33. The biopharmaceutical company had revenue of $29.18 million for the quarter, compared to analyst estimates of $36.65 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 173.28% and a negative net margin of 180.70%.

Nektar Therapeutics' top institutional shareholders include Nantahala Capital Management LLC (4.23%), Primecap Management Co. CA (3.00%), Woodline Partners LP (2.70%) and Millennium Management LLC (2.45%). Insiders that own company stock include Deep Track Capital, Lp, Howard W Robin, Mark Andrew Wilson, Jonathan Zalevsky, Jillian B Thomsen, Gil M Labrucherie, Robert Chess, Roy A Whitfield and Myriam Curet.
View institutional ownership trends
.

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nektar Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Exxon Mobil (XOM).

Company Calendar

Last Earnings
3/12/2025
Today
3/25/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:NKTR
Employees
220
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$4.92
High Stock Price Target
$7.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+491.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-276,060,000.00
Net Margins
-180.70%
Pretax Margin
-180.71%

Debt

Sales & Book Value

Annual Sales
$98.43 million
Price / Cash Flow
N/A
Book Value
$0.69 per share
Price / Book
1.20

Miscellaneous

Free Float
177,615,000
Market Cap
$154.65 million
Optionable
Optionable
Beta
0.65

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:NKTR) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners